Quick Answer
enGene Therapeutics Inc. reported Research And Development Expense of $94.48 million for the year ending 2025.
- enGene Therapeutics Inc. showed an increase of +146.6% in Research And Development Expense from 2024 to 2025.
- This data is from enGene Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on December 22, 2025.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 4 years of available data (2022 to 2025), enGene Therapeutics Inc.'s Research And Development Expense has grown by 510.8%.
- Historical annual values: Fiscal year 2025: $94.48 million | Fiscal year 2024: $38.32 million | Fiscal year 2023: $16.46 million | Fiscal year 2022: $15.47 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: